Purpose: This report provides new information regarding comprehensive drug testing of clinical biological specimens collected after suspected opioid overdoses in various cities across the United States.

Overview: Drug use can lead to adverse events and overdose scenarios where individuals present to emergency departments for clinical evaluation and/or treatment. The culprit can be traditional drugs (e.g., heroin, fentanyl, cocaine, methamphetamine) or novel psychoactive substances (NPS); however, proper drug testing methodologies must be employed for accurate identification and characterization. Street-level drug preparations can contain undeclared or unwanted substances, such as toxic adulterants or NPS, which can potentiate effects or lead to adverse reactions. Understanding emerging drug trends and drug testing results can help direct new or revised approaches to clinical treatment and harm reduction efforts.

Objective: A partnership between the American College of Medical Toxicology (ACMT) and the Center for Forensic Science Research and Education (CFSRE) was established to comprehensively assess the role and prevalence of synthetic opioids and other drugs among suspected overdose events in the United States.

Location: Portland, OR
Key Findings:
• 100% of samples were positive for at least one opioid
• Heroin (63%) was most commonly detected followed by fentanyl (50%)
• Combined opioid and stimulant use was common (63%)
• Combined opioid and benzodiazepine use was less common (13%)
• NPS: Clonazolam and Flubromazolam

Location: St. Louis, MO
Key Findings:
• 95% of samples were positive for at least one opioid
• Fentanyl (95%) was commonly detected followed by tramadol (24%)
• Combined opioid and stimulant use was common (62%)
• PCP was detected in combination with opioids and alone
• NPS: Clonazolam, Flualprazolam, Eutylone, para-Fluorofentanyl (41%)

Location: Bethlehem, PA
Key Findings:
• 96% of samples were positive for at least one opioid
• Fentanyl (87%) was commonly detected, followed by tramadol (22%) and heroin (13%)
• Combined opioid and stimulant use was observed (30%)
• Combined opioid and benzodiazepine use was observed (30%)
• NPS: Clonazolam and para-Fluorofentanyl

Location: Newark, NJ
Key Findings:
• 88% of samples were positive for at least one opioid
• Fentanyl (69%) was commonly detected, followed by methadone (41%), heroin (37%), and tramadol (22%)
• Xylazine was observed alongside fentanyl (31%)
• Combined opioid and stimulant use was observed (29%)
• PCP was detected (24%)
• NPS: Clonazolam, Etizolam, MDMB-4en-PINACA, ADB-BINACA, Tenocyclidine, and para-Fluorofentanyl

Location: New York, NY
Key Findings:
• 86% of samples were positive for at least one opioid
• Fentanyl (69%) was commonly detected, followed by methadone (41%), heroin (37%), and tramadol (22%)
• PCP was detected (24%)
• NPS: Clonazolam, Etizolam, MDMB-4en-PINACA, ADB-BINACA, Tenocyclidine, and para-Fluorofentanyl

Sample Source: Patients presented to emergency departments within ACMT’s Toxicology Investigators Consortium (ToxIC) experiencing a suspected opioid overdose. Residual, discarded biological samples were obtained for testing against an expansive library of drugs and other substances. Our findings provide a near real-time assessment of the drug market and allude to resulting implications on clinical institutions.

Testing: Analysis was performed via liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). The scope of testing targeted more than 900 drugs, including a vast majority of NPS and metabolites. Drug classes included opioids, stimulants, cannabinoids, and benzodiazepines, among others.

Acknowledgements: This report was prepared by Alex Manini, MD; Alex J. Krotulski, PhD; Sara E. Walton, MS; Paul Wax, MD; Jeffery Brent, MD, PhD; Kim Aldy, DO; Alexandra Amaducci, DO; Diane Calello, MD; Adrienne Hughes, MD; Evan Schwarz, MD; and Barry K. Logan, PhD, F-ABFT. The authors acknowledge ACMT personnel, ToxIC investigators, and CFSRE staff for their contributions. Funding was received from the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH), Award Number: R01DA048009. The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of NIDA, NIH, or other agencies. For more information about NPS Discovery, contact npsdiscovery@cfsre.org or visit www.npsdiscovery.org.